Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 10/20 | 0.56 |
| ▸ | NOS3 | P29474 | 8/20 | 0.56 |
| ▸ | NOS2 | P35228 | 8/20 | 0.56 |
| ▸ | DNM2 | P50570 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11447017 | 0.90 | NOS1 (0.52) | NOS1NOS3NOS2DNM2 | |
| SCHEMBL11454656 | 0.79 | DNM2 (0.55) | NOS1NOS3NOS2DNM2 | |
| SCHEMBL17985629 | 0.78 | TLR8 (0.69) | DNM2 | |
| SCHEMBL11187910 | 0.73 | DNM2 (0.55) | NOS1NOS3NOS2DNM2 | |
| SCHEMBL12330672 | 0.72 | DNM2 (0.53) | DNM2 | |
| SCHEMBL11446516 | 0.71 | DNM2 (0.46) | DNM2 | |
| Hydrochloric Acid SCHEMBL31338777 | 0.71 | NOS1 (0.97) | NOS1NOS3NOS2 | |
| SCHEMBL13989410 | 0.69 | TLR8 (0.61) | DNM2 | |
| SCHEMBL15743947 | 0.68 | CYP2C19 (0.46) | DNM2 | |
| SCHEMBL15834613 | 0.68 | DNM2 (0.59) | DNM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227333-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227333-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227333-B2 | Inhibition of OLIG2 activity | GLI2, ING2, GMFG | NOS1 3796/4885NOS3 3763/4885NOS2 2324/4885 |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | NOS1 3796/4885NOS3 3763/4885NOS2 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.